GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2006

Genetix Hikes Buy-Out Price for Applied Imaging for the Third Time

  • Genetix has upped its bid for Applied Imaging (AI) for the third time by about 26.5% from its original offer to $23.2 million. The amendment comes after an unnamed third party made an unsolicited bid that prompted AI to hike its asking price to $3.80 per share. AI plans to discuss the proposed acquisition on November 21, 2006.

    Genetix initially announced its plan to take over AI on September 1, 2006, for $18.3 million, or $3.06 per share. After the yet unnamed suitor came forth on October 23, AI boosted its consideration to $3.50 per share. Genetix accordingly raised its offer to $21.2 million, representing approximately $268,627 more than what AI asked. The bidding war continued with another unsolicited proposal seven days later that spurred AI to petition an amount of $3.70 per share. Genetix once again adjusted its buying price to $22.5 million, about $372,549 more than AI’s request.

    Genetix’ latest offer marks the largest upgrade over AI’s asking price of $3.80 per share at about $474,509. The company maintains that this acquisition will help it broaden its competencies in cell imaging and analysis. AI manufactures automated image capture and analysis systems for use in cytogenetics laboratories in the U.S., with a growing presence in the cancer pathology market.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?